JP7478975B2 - チカグレロル活性を逆転させる方法 - Google Patents

チカグレロル活性を逆転させる方法 Download PDF

Info

Publication number
JP7478975B2
JP7478975B2 JP2021515473A JP2021515473A JP7478975B2 JP 7478975 B2 JP7478975 B2 JP 7478975B2 JP 2021515473 A JP2021515473 A JP 2021515473A JP 2021515473 A JP2021515473 A JP 2021515473A JP 7478975 B2 JP7478975 B2 JP 7478975B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
ticagrelor
hours
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021515473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501368A5 (https=
JP2022501368A (ja
JPWO2020061465A5 (https=
Inventor
リー，ジョン
ジェームス バランス，デイヴィット
Original Assignee
エスエフジェイ ファーマ エックス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69887913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7478975(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エスエフジェイ ファーマ エックス，インコーポレイテッド filed Critical エスエフジェイ ファーマ エックス，インコーポレイテッド
Publication of JP2022501368A publication Critical patent/JP2022501368A/ja
Publication of JP2022501368A5 publication Critical patent/JP2022501368A5/ja
Publication of JPWO2020061465A5 publication Critical patent/JPWO2020061465A5/ja
Priority to JP2024062468A priority Critical patent/JP2024096134A/ja
Application granted granted Critical
Publication of JP7478975B2 publication Critical patent/JP7478975B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021515473A 2018-09-20 2019-09-20 チカグレロル活性を逆転させる方法 Active JP7478975B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024062468A JP2024096134A (ja) 2018-09-20 2024-04-09 チカグレロル活性を逆転させる方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862733892P 2018-09-20 2018-09-20
US62/733,892 2018-09-20
US201962806225P 2019-02-15 2019-02-15
US62/806,225 2019-02-15
US201962836373P 2019-04-19 2019-04-19
US62/836,373 2019-04-19
PCT/US2019/052173 WO2020061465A1 (en) 2018-09-20 2019-09-20 Methods of reversing ticagrelor activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024062468A Division JP2024096134A (ja) 2018-09-20 2024-04-09 チカグレロル活性を逆転させる方法

Publications (4)

Publication Number Publication Date
JP2022501368A JP2022501368A (ja) 2022-01-06
JP2022501368A5 JP2022501368A5 (https=) 2022-09-27
JPWO2020061465A5 JPWO2020061465A5 (https=) 2022-09-27
JP7478975B2 true JP7478975B2 (ja) 2024-05-08

Family

ID=69887913

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021515473A Active JP7478975B2 (ja) 2018-09-20 2019-09-20 チカグレロル活性を逆転させる方法
JP2024062468A Pending JP2024096134A (ja) 2018-09-20 2024-04-09 チカグレロル活性を逆転させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024062468A Pending JP2024096134A (ja) 2018-09-20 2024-04-09 チカグレロル活性を逆転させる方法

Country Status (13)

Country Link
US (1) US20210347915A1 (https=)
EP (2) EP4653465A3 (https=)
JP (2) JP7478975B2 (https=)
KR (2) KR20250161038A (https=)
CN (1) CN113194821B (https=)
AU (1) AU2019342755B2 (https=)
CA (1) CA3113654A1 (https=)
DK (1) DK3852617T3 (https=)
ES (1) ES3042247T3 (https=)
FI (1) FI3852617T3 (https=)
MX (1) MX2021003298A (https=)
PL (1) PL3852617T3 (https=)
WO (1) WO2020061465A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024096134A (ja) * 2018-09-20 2024-07-12 エスエフジェイ ファーマ エックス，インコーポレイテッド チカグレロル活性を逆転させる方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106715473B (zh) 2014-10-01 2021-11-23 免疫医疗有限公司 替格瑞洛的抗体及其使用方法
EP4337253A4 (en) * 2021-05-10 2025-03-19 Sfj Pharmaceuticals X, Ltd. Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody
KR102952285B1 (ko) 2021-07-13 2026-04-13 주식회사 엘지에너지솔루션 전지의 용접 상태 검사 방법
US20260022197A1 (en) * 2024-07-16 2026-01-22 SFJ Pharma X, Inc. Methods of reversing ticagrelor activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535252A (ja) 2014-10-01 2017-11-30 メディミューン リミテッド チカグレロルに対する抗体および使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03154867A (ja) * 1989-11-13 1991-07-02 Teijin Ltd １―メチルアデノシンの免疫学的測定方法，そのための測定試薬及び試薬キット
MX2013014035A (es) * 2011-06-01 2014-01-23 Astrazeneca Ab Nuevo co-cristal ticagrelor.
AU2013344796B2 (en) * 2012-11-16 2016-11-10 Novartis Ag Use of IL-1 beta binding antibodies for treating peripheral arterial disease
KR20220041957A (ko) * 2013-03-15 2022-04-01 아비에 도이치란트 게엠베하 운트 콤파니 카게 항-egfr 항체 약물 접합체 제형
AU2014265624B2 (en) * 2013-05-15 2019-09-12 Medimmune Limited Purification of recombinantly produced polypeptides
WO2016033424A1 (en) * 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
JP2018502894A (ja) * 2015-01-27 2018-02-01 アストラゼネカ アクチボラグ 心筋梗塞の病歴がある患者においてアテローム血栓性イベントを治療または予防する方法
KR101916956B1 (ko) * 2016-12-13 2018-11-08 보령제약 주식회사 티카그렐러의 신규한 고체 형태 및 이의 제조방법
CN110325211A (zh) * 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
BR112019018022A2 (pt) * 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
PL3852617T3 (pl) * 2018-09-20 2026-01-26 SFJ Pharma X, Inc. Zastosowanie fragmentów przeciwciała do odwrócenia aktywności tikagreloru

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535252A (ja) 2014-10-01 2017-11-30 メディミューン リミテッド チカグレロルに対する抗体および使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUCHANAN A; NEWTON P; PEHRSSON S; ET AL，STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF A SPECIFIC ANTIDOTE FOR TICAGRELOR，BLOOD，米国，AMERICAN SOCIETY OF HEMATOLOGY，2015年05月28日，VOL:125, NR:22，PAGE(S):3484 - 3490，http://dx.doi.org/10.1182/blood-2015-01-622928
Thomas MEYER and Helmuth HILZ，Eur. J. Biochem.，1986年，Vol.155，p.157-165

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024096134A (ja) * 2018-09-20 2024-07-12 エスエフジェイ ファーマ エックス，インコーポレイテッド チカグレロル活性を逆転させる方法

Also Published As

Publication number Publication date
ES3042247T3 (en) 2025-11-19
US20210347915A1 (en) 2021-11-11
WO2020061465A1 (en) 2020-03-26
EP3852617A1 (en) 2021-07-28
KR20210091698A (ko) 2021-07-22
CA3113654A1 (en) 2020-03-26
JP2024096134A (ja) 2024-07-12
EP3852617B1 (en) 2025-09-10
KR20250161038A (ko) 2025-11-14
AU2019342755A1 (en) 2021-05-06
DK3852617T3 (da) 2025-10-20
EP4653465A2 (en) 2025-11-26
JP2022501368A (ja) 2022-01-06
MX2021003298A (es) 2021-08-11
KR102880762B1 (ko) 2025-11-03
EP4653465A3 (en) 2026-01-07
EP3852617A4 (en) 2022-08-24
FI3852617T3 (fi) 2025-10-21
CN113194821B (zh) 2025-07-04
PL3852617T3 (pl) 2026-01-26
CN113194821A (zh) 2021-07-30
AU2019342755B2 (en) 2025-12-11

Similar Documents

Publication Publication Date Title
JP7478975B2 (ja) チカグレロル活性を逆転させる方法
US11147879B2 (en) Methods of treating or preventing stent thrombosis
JP2014077005A (ja) 抗血小板療法中の血小板抑制のメンテナンス
JP2026048712A (ja) 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
JP2022501368A5 (https=)
US20230192895A1 (en) Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody
AU2017355613B2 (en) Treatment regimens
Pickett et al. Prolonged Infusion of Eptifibatide as Bridge Therapy Between Bare‐Metal Stent Insertion and Cardiovascular Surgery: Case Report and Review of the Literature
JP2023541249A (ja) 治療用抗体製剤
US20200055942A1 (en) Treatment regimens
JPWO2020061465A5 (https=)
US20250032578A1 (en) Use of a pharmaceutical composition
Musgrave DOAC Reversal Agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230821

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240409

R150 Certificate of patent or registration of utility model

Ref document number: 7478975

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157